ATRX loss in glioma results in dysregulation of cell-cycle phase transition and ATM inhibitor radio-sensitization.

doi:10.1016/j.celrep.2021.110216

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

ATRX loss in glioma results in dysregulation of cell-cycle phase transition and ATM inhibitor radio-sensitization.

Cell reports - 11 Jan 2022

Qin Tingting, Mullan Brendan, Ravindran Ramya, Messinger Dana, Siada Ruby, Cummings Jessica R, Harris Micah, Muruganand Ashwath, Pyaram Kalyani, Miklja Zachary, Reiber Mary, Garcia Taylor, Tran Dustin, Danussi Carla, Brosnan-Cashman Jacqueline, Pratt Drew, Zhao Xinyi, Rehemtulla Alnawaz, Sartor Maureen A, Venneti Sriram, Meeker Alan K, Huse Jason T, Morgan Meredith A, Lowenstein Pedro R, Castro Maria G, Yadav Viveka Nand, Koschmann Carl

Abstract excerpt

ATRX, a chromatin remodeler protein, is recurrently mutated in H3F3A-mutant pediatric glioblastoma (GBM) and isocitrate dehydrogenase (IDH)-mutant grade 2/3 adult glioma. Previous work has shown that ATRX-deficient GBM cells show enhanced sensitivity to irradiation, but the etiology remains unclear. We find that ATRX binds the regulatory elements of cell-cycle phase transition genes in GBM cells, and there is a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Cycle Checkpoints

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Checkpoint Kinase 1

Share to Glioma

Share to Histones

Share to Isocitrate Dehydrogenase

Share to Neoplasm Recurrence, Local

Share to Primary Cell Culture

Share to X-linked Nuclear Protein

Source

Open in PubMed Open full text

Identifiers

PMID: 35021084
DOI: 10.1016/j.celrep.2021.110216
PMCID: PMC8759735

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ATRX loss in glioma results in dysregulation of cell-cycle phase transition and ATM inhibitor radio-sensitization.PMID 35021084Read ↗

Loss of ATRX confers DNA repair defects and PARP inhibitor sensitivitySemantic proximity Read ↗

Mutant ATRX: uncovering a new therapeutic target for glioma.Semantic proximity Read ↗

ATRX, a guardian of chromatinSemantic proximity Read ↗

MGMT function determines the differential response of ATR inhibitors with DNA-damaging agents in glioma stem cells for GBM therapySemantic proximity Read ↗

IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage responseSemantic proximity Read ↗

The Chromatin Remodeler ATRX: Role and Mechanism in Biology and CancerSemantic proximity Read ↗

Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas.Semantic proximity Read ↗

Mutations inhibiting KDM4B drive ALT activation in ATRX-mutated glioblastomas.Semantic proximity Read ↗

Trial Watch: Targeting ATM–CHK2 and ATR–CHK1 pathways for anticancer therapySemantic proximity Read ↗

Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling.Semantic proximity Read ↗

Emerging roles of ATRX in cancer.Semantic proximity Read ↗

ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.